🔗 Share this article

Given that the US proceeds with sweeping adjustments to its vaccination guidelines, a particular individual appears unexpectedly: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who rose to prominence by expressing skepticism about coronavirus shots in the pandemic and has zeroed in on alleged fatalities after Covid immunization in her brief tenure at the US Food and Drug Administration (FDA).

Proposed Changes to Pediatric Immunization Program

Health officials had intended to unveil sweeping revisions to the childhood immunization program in December, aligning the US with the Danish immunization schedule, it is understood – a substantial departure that would put the US out of step with many the global community with insufficient data for improved outcomes. The planned update has been pushed back until the next year.

In place of the top vaccines chief, Tracy Beth Høeg is scheduled to speak at the meeting. She was recently named interim head of the FDA’s CDER, the fifth individual to lead the division this year.

Consolidating Power at the Agency

The acting appointment might represent a strengthened alliance between the pharmaceutical and biologics branches as Høeg and Dr. Prasad consolidate power at the agency – and it points to a greater focus upon reevaluating long-standing immunizations at the FDA.

The new acting director has often pushed for discontinuing some childhood shot schedules in the US to become more like Denmark, a nation with universal health coverage and a population roughly the population of Wisconsin’s.

So far public appearances, she has kept her attention on immunizations – traditionally the domain of Prasad, chief of the FDA’s vaccine center – as opposed to medication approval.

Concerns Over Expertise

Høeg has little discernible background in pharmaceutical research, regulation or administrative roles, which has been customary for former directors of the CBER. She has worked at the FDA as a senior adviser to the agency head and the vaccine center since March.

“She appears not to have the requisite experience” for leading the pharmaceutical oversight division, said Dr. Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in leading a sizeable institution. She is not an expert in drug approvals.”

Previous directors of the center would “be deeply familiar with legal statutes and the science of drug development”, said a former acting FDA commissioner. “Clearly, she has not acquired the type of experience that previous people who ran CBER have had.”

This division has an vast portfolio at the FDA, Woodcock stated.

“Everybody just pays attention on the innovative therapies, but the generic drug division clears thousands of generic medications. There is also a biosimilars program, non-prescription drug unit and more, and each of these must be looked after,” Woodcock noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Furthermore, a substantial leadership component to the role, which manages in excess of 5,000 personnel. “It is a massive administrative position, if you perform it correctly,” she added.

Agency Reaction and Contentious Initiatives

When asked about inquiries about Høeg’s credentials and whether this appointment signifies increased cooperation among FDA leaders on immunizations, a representative said that the “inquiries are based on flawed premises”.

“Her experience matches the duties of her role,” the spokesperson explained, pointing to the months Dr. Høeg spent guiding the agency head on “pharmaceutical safety and regulatory science, including computational safety modeling and immunization monitoring”.

As acting director, Dr. Høeg assumes responsibility for the agency head's new fast-track approval initiative, a contentious expedited medication authorization process that allegedly troubled her former heads. “By what process are these drugs being chosen for this expedited pathway? Who is making the decisions?” Howard said. “There’s a lot of secrecy occurring at the FDA right now.”

In general, he stated, “the agency looks to be trending towards less stringent oversight of most medications, aside from vaccines.”

Documented Track Record on Vaccines

Regarding vaccines, Høeg has a more established, if problematic, past, critics observe. She released a analysis using non-validated volunteer-provided data to determine the incidence of myocarditis after COVID-19 immunization. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccines are riskier than they are.

Among her “wish list” for the current administration featured altering regulations for new vaccines and ending “unnecessary” immunizations, she remarked after the election on a online show. At the agency, Dr. Høeg has according to sources proposed preventing teenage boys from getting Covid vaccinations.

“She’s an complete true believer who starts off with her beliefs and works backwards to retrofit the evidence in a very disingenuous, dishonest fashion,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Høeg became part of other contrarians, {like|